Clarence Adoo, MD
Hematology & Oncology · Glendale, AZNPI 1063480036
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Global Blood Therapeutics, Inc. at 49.6% of the total. Reporting peaked in 2020 at $1,565 and has fallen 98.7% since, to $21 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AZ, where the typical reported total is $6,870.
Across 96 payments — averaging $31.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Global Blood Therapeutics, Inc.$2K
- Merck$225
- Johnson & Johnson$207
- Amgen$140
- Pfizer$136
- E.r. Squibb & Sons, L.L.C.$92
- plus $744 from 24 others
Across 17 payments — averaging $3262.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$35K
- Pfizer$9K
- Immunomedics, Inc.$8K
- Pharmacyclics LLC, An Abbvie Company$2K
What the payments were for
- Speaking & faculty fees$1,52050%
- Food & beverage$1,51449%
- Education$291%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Global Blood Therapeutics, Inc. | 2 | $1,520 |
| Merck | 14 | $225 |
| Johnson & Johnson(2 entities) | 14 | $207 |
| Amgen | 7 | $140 |
| Pfizer | 12 | $136 |
| E.r. Squibb & Sons, L.L.C. | 6 | $92 |
| Bayer | 4 | $76 |
| AbbVie | 3 | $68 |
| Novartis | 4 | $58 |
| Teva Pharmaceuticals USA, Inc. | 4 | $53 |
| Bristol Myers Squibb | 2 | $51 |
| Stemline Therapeutics Inc. | 2 | $48 |
| Tesaro, Inc. | 2 | $47 |
| Boehringer Ingelheim | 2 | $39 |
| Astellas Pharma US Inc | 2 | $34 |
| Seagen Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Exelixis Inc. | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Sanofi | 1 | $16 |
| Taiho Oncology, Inc. | 1 | $15 |
| Boston Scientific | 1 | $13 |
| Gilead | 1 | $12 |
| Verastem, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OXBRYTA$1,520
How this compares
$3,063 in reported general payments places this provider in the 40th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 25 | $451,927 |
| IbrancePalbociclib | 16 | $249,296 |
| OxbrytaVoxelotor | 17 | $202,280 |
| JakafiRuxolitinib Phosphate | 13 | $158,422 |
| Abiraterone Acetate | 11 | $36,867 |
| EliquisApixaban | 33 | $27,822 |
| XareltoRivaroxaban | 31 | $23,044 |
| Anastrozole | 28 | $898 |
| Letrozole | 15 | $495 |
| Raloxifene Hcl | 12 | $464 |
| Hydroxyurea | 11 | $338 |
| Dexamethasone | 16 | $262 |
| Prednisone | 20 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $51 | $451,92725 claims |
| PfizerIbrance, Eliquis | $136 | $277,11849 claims |
| Global Blood Therapeutics, Inc.Oxbryta | $1,520 | $202,28017 claims |
| Incyte CorporationJakafi | $18 | $158,42213 claims |
| Johnson & JohnsonXarelto | $207 | $23,04431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Glendale
- Elisa BomgaarsGlendale$48K
- Rajesh BagaiGlendale$30K
- Sujith KalmadiChandler$1.4M
- Jeffrey SchriberScottsdale$715K
- Javier MunozPhoenix$638K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Sumit MadanGilbert$422K
- Christopher ChenTucson$370K
- Rachna ShroffTucson$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.